Camilo Jimenez

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. pmc Medullary thyroid carcinoma: molecular signaling pathways and emerging therapies
    Karen Gómez
    Department of Endocrinology, Hospital San Juan de Dios, Avenida 14, Calles 6 Y 7 Paseo Colon, 1475 1000 San José, Costa Rica
    J Thyroid Res 2011:815826. 2011
  2. ncbi request reprint The characterization of pheochromocytoma and its impact on overall survival in multiple endocrine neoplasia type 2
    Sonali Thosani
    MD, AssociateDepartment of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, 1400 Pressler Street Unit 1461, Houston, TX 77030
    J Clin Endocrinol Metab 98:E1813-9. 2013
  3. ncbi request reprint Current and future treatments for malignant pheochromocytoma and sympathetic paraganglioma
    Camilo Jimenez
    Department of Endocrine Neoplasia and Hormonal Disorders, Unit 1461, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Curr Oncol Rep 15:356-71. 2013
  4. pmc An unusual cause of alveolar hemorrhage post hematopoietic stem cell transplantation: a case report
    Sachin Gupta
    Department of Pulmonary Medicine, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    BMC Cancer 6:87. 2006
  5. doi request reprint Inhibition of growth hormone receptor activation by pegvisomant may increase bone density in acromegaly
    C Jimenez
    Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Horm Metab Res 43:55-61. 2011
  6. doi request reprint Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors
    Camilo Jimenez
    Department of Endocrine Neoplasia and Hormonal Disorders, Unit 435, The University of Texas M D Anderson Cancer, Center, Houston, Texas 77030, USA
    J Clin Endocrinol Metab 94:386-91. 2009
  7. doi request reprint Adrenocortical carcinoma: clinical outcomes and prognosis of 330 patients at a tertiary care center
    Montserrat Ayala-Ramirez
    Department of Endocrine Neoplasia and Hormonal Disorders, Unit 1461, The University of Texas MD Anderson Cancer Center UTMDACC, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
    Eur J Endocrinol 169:891-9. 2013
  8. ncbi request reprint Pheochromocytoma and medullary thyroid carcinoma: a new genotype-phenotype correlation of the RET protooncogene 891 germline mutation
    Camilo Jimenez
    The University of Texas MD Anderson Cancer Center, Department of Endocrine Neoplasia and Hormonal Disorders, 1515 Holcombe Boulevard, Unit 435, Houston, Texas 77030, USA
    J Clin Endocrinol Metab 89:4142-5. 2004
  9. doi request reprint Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators
    Montserrat Ayala-Ramirez
    Department of Endocrine Neoplasia and Hormonal Disorders, Unit 1461, The University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Houston, Texas 77030, USA
    J Clin Endocrinol Metab 96:717-25. 2011
  10. pmc Clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or sympathetic extra-adrenal paragangliomas: insights from the largest single-institutional experience
    Montserrat Ayala-Ramirez
    Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 118:2804-12. 2012

Detail Information

Publications56

  1. pmc Medullary thyroid carcinoma: molecular signaling pathways and emerging therapies
    Karen Gómez
    Department of Endocrinology, Hospital San Juan de Dios, Avenida 14, Calles 6 Y 7 Paseo Colon, 1475 1000 San José, Costa Rica
    J Thyroid Res 2011:815826. 2011
    ..In this paper, we explore newly understood molecular pathways and the most promising emerging therapies that may change the management of MTC...
  2. ncbi request reprint The characterization of pheochromocytoma and its impact on overall survival in multiple endocrine neoplasia type 2
    Sonali Thosani
    MD, AssociateDepartment of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, 1400 Pressler Street Unit 1461, Houston, TX 77030
    J Clin Endocrinol Metab 98:E1813-9. 2013
    ..Pheochromocytoma (PHEO) occurs in 50% of patients with multiple endocrine neoplasia type 2 (MEN2). It is unknown if the presence of PHEO is associated with more aggressive medullary thyroid cancer (MTC)...
  3. ncbi request reprint Current and future treatments for malignant pheochromocytoma and sympathetic paraganglioma
    Camilo Jimenez
    Department of Endocrine Neoplasia and Hormonal Disorders, Unit 1461, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Curr Oncol Rep 15:356-71. 2013
    ....
  4. pmc An unusual cause of alveolar hemorrhage post hematopoietic stem cell transplantation: a case report
    Sachin Gupta
    Department of Pulmonary Medicine, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    BMC Cancer 6:87. 2006
    ..Diffuse alveolar hemorrhage associated with Strongyloides stercoralis hyperinfection in stem cell transplant patients has been rarely reported...
  5. doi request reprint Inhibition of growth hormone receptor activation by pegvisomant may increase bone density in acromegaly
    C Jimenez
    Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Horm Metab Res 43:55-61. 2011
    ..016) and significant increases in the right hip BMD from baseline to 18 months (p=0.032). The range of the increases was 4.3-17.8% at 7 years. It is concluded that successful treatment of acromegaly with pegvisomant increases BMD...
  6. doi request reprint Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors
    Camilo Jimenez
    Department of Endocrine Neoplasia and Hormonal Disorders, Unit 435, The University of Texas M D Anderson Cancer, Center, Houston, Texas 77030, USA
    J Clin Endocrinol Metab 94:386-91. 2009
    ..von Hippel-Lindau disease is characterized by highly vascularized tumors of multiple organs...
  7. doi request reprint Adrenocortical carcinoma: clinical outcomes and prognosis of 330 patients at a tertiary care center
    Montserrat Ayala-Ramirez
    Department of Endocrine Neoplasia and Hormonal Disorders, Unit 1461, The University of Texas MD Anderson Cancer Center UTMDACC, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
    Eur J Endocrinol 169:891-9. 2013
    ..Adrenocortical carcinoma (ACC) is a rare malignancy with a poor prognosis. Herein, we describe the clinical features and outcomes for a large series of ACC patients...
  8. ncbi request reprint Pheochromocytoma and medullary thyroid carcinoma: a new genotype-phenotype correlation of the RET protooncogene 891 germline mutation
    Camilo Jimenez
    The University of Texas MD Anderson Cancer Center, Department of Endocrine Neoplasia and Hormonal Disorders, 1515 Holcombe Boulevard, Unit 435, Houston, Texas 77030, USA
    J Clin Endocrinol Metab 89:4142-5. 2004
    ..These findings indicate that patients with this mutation should be screened for pheochromocytoma...
  9. doi request reprint Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators
    Montserrat Ayala-Ramirez
    Department of Endocrine Neoplasia and Hormonal Disorders, Unit 1461, The University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Houston, Texas 77030, USA
    J Clin Endocrinol Metab 96:717-25. 2011
    ..Pheochromocytomas and sympathetic paragangliomas are rare neuroendocrine tumors for which no precise histological or molecular markers have been identified to differentiate benign from malignant tumors...
  10. pmc Clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or sympathetic extra-adrenal paragangliomas: insights from the largest single-institutional experience
    Montserrat Ayala-Ramirez
    Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 118:2804-12. 2012
    ....
  11. doi request reprint Posterior retroperitoneoscopic adrenalectomy is a safe and effective alternative to transabdominal laparoscopic adrenalectomy for pheochromocytoma
    Paxton V Dickson
    Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Surgery 150:452-8. 2011
    ..Posterior retroperitoneoscopic adrenalectomy (PRA) is an alternative minimally invasive technique; however, there is a lack of data regarding the appropriateness of this approach in patients with PHEO...
  12. pmc Multiple endocrine neoplasia type 2B with a RET proto-oncogene A883F mutation displays a more indolent form of medullary thyroid carcinoma compared with a RET M918T mutation
    Sina Jasim
    Department of Endocrine Neoplasia and Hormonal Disorders, University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Thyroid 21:189-92. 2011
    ..Further characterization of the clinical behavior of RET-A883F mutation is warranted. We present the clinical data for a family with MEN-2B associated with RET-A883F mutation...
  13. pmc A retrospective cohort analysis of the efficacy of adjuvant radiotherapy after primary surgical resection in patients with adrenocortical carcinoma
    Mouhammed Amir Habra
    Department of Endocrine Neoplasia and Hormonal Disorders, Unit 1461, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
    J Clin Endocrinol Metab 98:192-7. 2013
    ..Adrenocortical carcinoma (ACC) is a rare malignancy with high recurrence and mortality rates. The role of adjuvant radiation therapy (RT) to improve outcome remains unclear...
  14. pmc The noninvestigational use of tyrosine kinase inhibitors in thyroid cancer: establishing a standard for patient safety and monitoring
    Aubrey A Carhill
    Department of Medicine, Division of Endocrinology, Diabetes, and Metabolism, Baylor College of Medicine, Houston, Texas 77030, USA
    J Clin Endocrinol Metab 98:31-42. 2013
    ....
  15. doi request reprint A novel von Hippel-Lindau point mutation presents as apparently sporadic pheochromocytoma
    Thereasa A Rich
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Cancer Invest 26:642-6. 2008
    ..The nearly asymptomatic patient's father also carries the same mutation. Similar to other mutations localized in the same codon, the Gly104Val VHL mutation seems to have an attenuated disease phenotype...
  16. doi request reprint Long-term outcomes of surgical treatment for hereditary pheochromocytoma
    Elizabeth G Grubbs
    Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030 4008, USA
    J Am Coll Surg 216:280-9. 2013
    ..An intact and viable cortical remnant after bilateral pheochromocytoma resection can eliminate the necessity for steroid dependency, but can increase the risk of pheochromocytoma recurrence...
  17. doi request reprint Greater than age-predicted functional deficits in older patients with primary hyperparathyroidism
    G Stephen Morris
    Department of Rehabilitation Services, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Endocr Pract 18:450-5. 2012
    ..To compare the functional capacity of "asymptomatic" patients with primary hyperparathyroidism (PHPT) with normative values of healthy age-matched subjects...
  18. doi request reprint Posterior retroperitoneoscopic adrenalectomy: a contemporary American experience
    Paxton V Dickson
    Department of Surgical Oncology, MD Anderson Cancer Center, Houston, TX 77030, USA
    J Am Coll Surg 212:659-65; discussion 665-7. 2011
    ..The operation requires that surgeons learn a new approach with few similarities to anterior adrenalectomy. This study reports a large series of PRAs incorporated into surgical care using a team-model approach...
  19. pmc Role of salvage targeted therapy in differentiated thyroid cancer patients who failed first-line sorafenib
    Ramona Dadu
    Departments of Endocrine Neoplasia and Hormonal Disorders R D, S G W, N L B, M I H, C J, M A H, R V S, A K Y, G J C, S I S, M E C, Diagnostic Radiology C D, and Biostatistics M H, The University of Texas M D Anderson Cancer Center and Department of Endocrinology, Diabetes, and Metabolism R D, Baylor College of Medicine, Houston, Texas 77030
    J Clin Endocrinol Metab 99:2086-94. 2014
    ..Sorafenib, a tyrosine kinase inhibitor, is a common first-line therapy for advanced differentiated thyroid cancer (DTC). However, responses are not durable and drug toxicity remains a problem...
  20. ncbi request reprint Paraganglioma syndrome type 1 in a patient with Carney-Stratakis syndrome
    Montserrat Ayala-Ramirez
    Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1461, Houston, TX 77030, USA
    Nat Rev Endocrinol 6:110-5. 2010
    ..The patient underwent surgery, which confirmed a malignant neck paraganglioma with metastasis to a cervical lymph node. He had no family history of carotid body tumors or pheochromocytoma...
  21. doi request reprint Parathyroidectomy improves functional capacity in "asymptomatic" older patients with primary hyperparathyroidism: a randomized control trial
    G Stephen Morris
    Department of Rehabilitation Services, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Ann Surg 251:832-7. 2010
    ....
  22. pmc Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas
    Montserrat Ayala-Ramirez
    Department of Endocrine Neoplasia and Hormonal Disorders, Unit 1461, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
    J Clin Endocrinol Metab 97:4040-50. 2012
    ..Patients with progressive metastatic pheochromocytomas (PHEOs) or sympathetic paragangliomas (SPGLs) face a dismal prognosis. Current systemic therapies are limited...
  23. ncbi request reprint Bone metastases and skeletal-related events in patients with malignant pheochromocytoma and sympathetic paraganglioma
    Montserrat Ayala-Ramirez
    Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    J Clin Endocrinol Metab 98:1492-7. 2013
    ..There is limited information on the clinical effects of BM and SREs in patients with malignant pheochromocytoma or sympathetic paraganglioma (PHEO/sPGL)...
  24. ncbi request reprint Robotic-assisted retroperitoneoscopic adrenalectomy: making a good procedure even better
    Paxton V Dickson
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Am Surg 79:84-9. 2013
    ..We believe these features may optimize the ability to maintain a vascularized remnant during minimally invasive cortical-sparing adrenalectomy...
  25. doi request reprint Fatal hypoglycemia in malignant pheochromocytoma: direct glucose consumption as suggested by (18)F-2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography imaging
    Mouhammed Amir Habra
    Department of Endocrine Neoplasia and Hormonal Disorders, Unit 1461, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Endocrine 37:209-12. 2010
    ..Nuclear medicine imaging techniques can illustrate the pathophysiology of hypoglycemia in such cases...
  26. pmc Cushing syndrome secondary to ectopic adrenocorticotropic hormone secretion: the University of Texas MD Anderson Cancer Center Experience
    Shamim Ejaz
    Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Cancer 117:4381-9. 2011
    ..In this report, the authors have described their experience with CS-EAS at The University of Texas MD Anderson Cancer Center to further enhance the current understanding and management of this syndrome...
  27. doi request reprint A catecholamine crisis on Mount Kilimanjaro: a hypoxia effect?
    Montserrat Ayala-Ramirez
    Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Travel Med 17:424-6. 2010
    ..We describe an individual with a paraganglioma complicated by a catecholamine crisis that occurred on the summit of Mount Kilimanjaro...
  28. pmc Efficacy and tolerability of different starting doses of sorafenib in patients with differentiated thyroid cancer
    Ramona Dadu
    Departments of Endocrine Neoplasia and Hormonal Disorders and Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA Department of Endocrinology, Diabetes and Metabolism, Baylor College of Medicine, Houston, Texas, USA
    Oncologist 19:477-82. 2014
    ..908) in group 1 and group 2, respectively. Conclusion. Efficacy and tolerability of sorafenib in treatment-naïve DTC patients does not appear to be negatively influenced by lower starting daily doses. ..
  29. ncbi request reprint Expression analysis of fibroblast growth factor-23, matrix extracellular phosphoglycoprotein, secreted frizzled-related protein-4, and fibroblast growth factor-7: identification of fibroblast growth factor-23 and matrix extracellular phosphoglycoprotein a
    Mouhammed Amir Habra
    Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Endocr Pract 14:1108-14. 2008
    ..To evaluate the expression of various phosphaturic factors in the tumor of a patient with tumor-induced osteomalacia (TIO) and to analyze serum levels of fibroblast growth factor (FGF)-23 in TIO and healthy subjects...
  30. doi request reprint Management of medullary thyroid carcinoma and MEN2 syndromes in childhood
    Steven G Waguespack
    The Department of Endocrine Neoplasia and Hormonal Disorders, PO Box 301402, Unit 1461, Houston, TX 77230 1402, USA
    Nat Rev Endocrinol 7:596-607. 2011
    ..To optimize care and to facilitate ongoing research, children with MTC and the MEN2 syndromes are optimally treated at tertiary centers with multidisciplinary expertise...
  31. doi request reprint Management of medullary thyroid carcinoma
    Camilo Jimenez
    Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Unit 435, 1515 Holcombe Boulevard, Houston, TX 77030 4009, USA
    Endocrinol Metab Clin North Am 37:481-96, x-xi. 2008
    ....
  32. doi request reprint Preoperative serum osteocalcin may predict postoperative elevated parathyroid hormone in patients with primary hyperparathyroidism
    Nahid Rianon
    Department of Family and Community Medicine, University of Texas Medical School at Houston, 6431 Fannin Street JJL324, Houston, TX 77030, USA
    World J Surg 36:1320-6. 2012
    ..Predicting which patients may need treatment is difficult. This study investigated whether preoperative serum osteocalcin (OC), a bone turnover marker involved in mineralization, can predict POePTH...
  33. pmc A novel SDHB mutation associated with hereditary head and neck paraganglioma
    Brandon W Peck
    Department of Medicine, Baylor College of Medicine, Houston, Texas, USA
    Laryngoscope 121:2572-5. 2011
    ..To describe a novel germline mutation in the succinate dehydrogenase subunit B (SDHB) gene...
  34. ncbi request reprint Preoperative vitamin D replacement therapy in primary hyperparathyroidism: safe and beneficial?
    Elizabeth G Grubbs
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Tex, USA
    Surgery 144:852-8; discussion 858-9. 2008
    ..The significance of vitamin D deficiency with primary hyperparathyroidism (PHPT) remains unclear. The safety and value of preoperative vitamin D (Vit D) replacement is unknown...
  35. doi request reprint Adrenal ganglioneuroma: features and outcomes of 27 cases at a referral cancer centre
    Hassan Shawa
    Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Clin Endocrinol (Oxf) 80:342-7. 2014
    ..Adrenal ganglioneuroma (AGN) is a rare neurogenic tumour that can mimic other adrenal neoplasms. Limited information, mostly derived from small cases series, is available for AGN...
  36. ncbi request reprint Posterior retroperitoneoscopic adrenalectomy: preferred technique for removal of benign tumors and isolated metastases
    Nancy D Perrier
    Department of Surgical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA
    Ann Surg 248:666-74. 2008
    ..This anatomically direct approach, popularized by Walz, minimizes dissection and affords early access to the adrenal vein. We report the largest experience to date of PRA in the United States...
  37. doi request reprint Novel germline SDHD mutation: diagnosis and implications to the patient
    Jeena Varghese
    Departments of Endocrine Neoplasia and Hormonal Disorders, Unit 1461, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Fam Cancer 10:365-71. 2011
    ..His blood pressure normalized and he discontinued antihypertensive medications after surgery. He is currently on replacement therapy with hydrocortisone and fludrocortisone...
  38. pmc Malignant head and neck paragangliomas: is there an optimal treatment strategy?
    Daniel J Moskovic
    Scott Department of Urology, Baylor College of Medicine, Houston, Texas, USA
    Head Neck Oncol 2:23. 2010
    ..Little is known about management and prognosis for malignant head & neck paragangliomas. We reviewed records of these patients to determine optimal treatment strategies...
  39. doi request reprint Skeletal sequelae of cancer and cancer treatment
    Charles J Stava
    Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas M D Anderson Cancer Center, Unit 1461, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    J Cancer Surviv 3:75-88. 2009
    ..Skeletal disorders are often associated with advancing age, but these effects can be exacerbated by exposure to cancer and its treatment. This review will explore the cancer and cancer treatment-related causes of skeletal disorders...
  40. ncbi request reprint A miRNA signature associated with human metastatic medullary thyroid carcinoma
    Libero Santarpia
    Departments of Endocrine Neoplasia and Hormonal Disorders Experimental Therapeutics Urology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA Department of Oncology, The University of Naples, Naples, Italy Department of Pathology, Centro Oncologico Fiorentino, Sesto Fiorentino, Florence, Italy Verna and Marrs McLean Department of Biochemistry and Molecular Biology Baylor College of Medicine, Houston, Texas, USA Department of Oncology, Istituto Toscano Tumori, Hospital of Prato, Prato, Italy Department of Gynecologic Oncology, Center for RNA Interference and Non coding RNAs, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA Department of Endocrinology, University of Messina, Messina, Italy Department of Pathology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA Department of Internal Medicine, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Endocr Relat Cancer 20:809-23. 2013
    ..Our data identify a robust miRNA signature associated with metastatic MTC and distinct biological processes, e.g., TGFβ signalling pathway, providing new potential insights into the mechanisms of MTC metastasis...
  41. doi request reprint Benign familial hypocalciuric hypercalcemia
    Jeena Varghese
    Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Endocr Pract 17:13-7. 2011
    ..To review the pathophysiology, clinical features, diagnosis, and management options for benign familial hypocalciuric hypercalcemia...
  42. ncbi request reprint A novel point mutation of the RET protooncogene involving the second intracellular tyrosine kinase domain in a family with medullary thyroid carcinoma
    Camilo Jimenez
    Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 435, Houston, TX 77030, USA
    J Clin Endocrinol Metab 89:3521-6. 2004
    ..Here, we describe a novel missense mutation of the RET protooncogene that substitutes arginine for proline at codon 912 of the intracellular tyrosine kinase domain in a family with medullary thyroid carcinoma...
  43. ncbi request reprint Parathyroid carcinoma: a 22-year experience
    Naifa L Busaidy
    joint Baylor College of Medicine The University of Texas M D Anderson Cancer Center Training Program in Endocrinology, Diabetes, and Metabolism, Houston, Texas, USA
    Head Neck 26:716-26. 2004
    ..Treatment strategies generally derive from clinical and anecdotal experiences. We report our experience with this entity...
  44. ncbi request reprint Follow-up of pituitary tumor volume in patients with acromegaly treated with pegvisomant in clinical trials
    Camilo Jimenez
    Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Eur J Endocrinol 159:517-23. 2008
    ..We present details on 9 of 304 patients in clinical trials with pegvisomant who experienced tumor growth within the first year of treatment...
  45. ncbi request reprint Primary hyperparathyroidism and osteosarcoma: examination of a large cohort identifies three cases of fibroblastic osteosarcoma
    Camilo Jimenez
    Department of Endocrinology, Diabetes, and Metabolism, Baylor College of Medicine, Houston, Texas, USA
    J Bone Miner Res 20:1562-8. 2005
    ..However, the presence of hyperparathyroidism may modify the histologic and cytologic features of osteosarcoma...
  46. ncbi request reprint Peer-reviewed, evidence-based analysis of vitamin D and primary hyperparathyroidism
    Storm Weaver
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, PO Box 301402, Houston, TX 77230 1402, USA
    World J Surg 33:2292-302. 2009
    ..New understanding about the effect of vitamin D on parathyroid hormone regulation may provide an opportunity to better understand the coexistence of PHPT and vitamin D deficiency...
  47. doi request reprint Impact of surgical resection for subdiaphragmatic paragangliomas
    Shabirhusain S Abadin
    Department of Surgical Oncology, Unit 1484, The University of Texas MD Anderson Cancer Center, P O Box 301402, Houston, TX, 77230 1402, USA
    World J Surg 38:733-41. 2014
    ..Subdiaphragmatic paraganglioma is a rare neuroendocrine tumor for which scarce data exist regarding long-term patient outcome following resection. The aim of this study was to determine the association of surgical resection with survival...
  48. ncbi request reprint Update on medullary thyroid cancer
    Mimi I Hu
    Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1461, Houston, TX 77030, USA
    Endocrinol Metab Clin North Am 43:423-42. 2014
    ..Developments in understanding the pathogenesis of MTC will hopefully lead to more effective and less toxic treatments of this rare but difficult to treat cancer. ..
  49. ncbi request reprint Bone loss in patients with breast or prostate cancer
    Mimi I Hu
    Department of Endocrine Neoplasia, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 435, Houston, TX 77030, USA
    Curr Osteoporos Rep 5:170-8. 2007
    ....
  50. doi request reprint A novel nomenclature to classify parathyroid adenomas
    Nancy D Perrier
    Department of Surgical Oncology, Unit 444, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    World J Surg 33:412-6. 2009
    ..We developed a nomenclature that provides a precise means of communicating the most frequently encountered parathyroid adenoma locations...
  51. doi request reprint Endocrine sequelae of cancer and cancer treatments
    Charles J Stava
    Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas M D Anderson Cancer Center, Unit 435, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    J Cancer Surviv 1:261-74. 2007
    ..This review will explore the endocrinologic adverse effects from non-endocrine cancer therapies...
  52. ncbi request reprint Genetic testing in endocrinology: lessons learned from experience with multiple endocrine neoplasia type 2 (MEN2)
    Camilo Jimenez
    Division of Internal Medicine, Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas M D Anderson Cancer Center, Box 433, 1515 Holcombe Blvd, Houston, TX, USA
    Growth Horm IGF Res 14:S150-7. 2004
    ....
  53. doi request reprint Random postoperative day-3 cortisol concentration as a predictor of hypothalamic-pituitary-adrenal axis integrity after transsphenoidal surgery
    Maryam I Khan
    Department of Endocrine Neoplasia and Hormonal Disorders, University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Endocr Pract 17:717-26. 2011
    ..To determine whether a random postoperative day-3 cortisol value of 10 μg/dL or greater is predictive of adrenal sufficiency 3 to 10 weeks after transsphenoidal surgery (TSS) and during long-term clinical follow-up...
  54. ncbi request reprint Prospective, randomized, controlled trial of parathyroidectomy versus observation in patients with "asymptomatic" primary hyperparathyroidism
    Nancy D Perrier
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77230 1402, USA
    Surgery 146:1116-22. 2009
    ..The aim of this study was to determine the impact of parathyroidectomy (PTX) on brain function and sleep in "asymptomatic" PHPT patients...
  55. doi request reprint Poor survival outcome with moderate and severe hypercalcemia in gynecologic malignancy patients
    Atthapon Jaishuen
    Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 1439, USA
    Int J Gynecol Cancer 19:178-85. 2009
    ..Determine the incidence of hypercalcemia in gynecologic malignancy patients and their survival outcome...
  56. ncbi request reprint Bone Loss in Lymphoma Patients Prior to Receiving Front-line Therapy
    Jason R Westin
    Division of Cancer Medicine, University of Texas M D Anderson Cancer Center, Houston, TX
    Clin Lymphoma Myeloma Leuk 10:E32. 2010
    ..The portion of all lymphoma patients with baseline osteopenia in our trial, prior to any therapy, is striking and argues for baseline screening of all patients...